4//SEC Filing
KAKKIS EMIL D 4
Accession 0001209191-23-053351
CIK 0001515673other
Filed
Oct 22, 8:00 PM ET
Accepted
Oct 23, 5:14 PM ET
Size
10.4 KB
Accession
0001209191-23-053351
Insider Transaction Report
Form 4
KAKKIS EMIL D
DirectorPresident & CEO10% Owner
Transactions
- Exercise/Conversion
Common Stock
2023-10-19$6.86/sh+47,853$328,272→ 647,029 total - Sale
Common Stock
2023-10-19$33.52/sh−47,853$1,604,033→ 599,743 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-10-19−47,853→ 0 totalExercise: $6.86Exp: 2023-11-01→ Common Stock (47,853 underlying)
Holdings
- 2,263,985(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.57 to $34.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Includes 567 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2023.
- [F4]Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- [F5]The option vested with respect to 1/4th of the shares on the first anniversary of the grant date of the option and 1/48th of the shares thereafter such that the option fully vested on the fourth anniversary of the grant date.
Documents
Issuer
Ultragenyx Pharmaceutical Inc.
CIK 0001515673
Entity typeother
Related Parties
1- filerCIK 0001248093
Filing Metadata
- Form type
- 4
- Filed
- Oct 22, 8:00 PM ET
- Accepted
- Oct 23, 5:14 PM ET
- Size
- 10.4 KB